American Association for Cancer Research
Browse
00085472can183622-sup-212292_2_supp_5547185_ps309n.pdf (6.14 MB)

Figure S3 from CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms

Download (6.14 MB)
journal contribution
posted on 2023-03-31, 02:24 authored by Joseph Castillo, Esther Wu, Christopher Lowe, Shrividhya Srinivasan, Ron McCord, Marie-Claire Wagle, Sangeeta Jayakar, Melissa Gonzalez Edick, Jeffrey Eastham-Anderson, Bonnie Liu, Katherine E. Hutchinson, Wendell Jones, Matthew P. Stokes, Somayeh S. Tarighat, Thomas Holcomb, Andrew Glibicky, F. Anthony Romero, Steven Magnuson, Shih-Min A. Huang, Vicki Plaks, Jennifer M. Giltnane, Mark R. Lackner, Zineb Mounir

Supplementary figure 3 shows H3K27 acetylation ChIPseq QC analyses.

History

ARTICLE ABSTRACT

Regulatory T cells (Treg) are immunosuppressive and negatively impact response to cancer immunotherapies. CREB-binding protein (CBP) and p300 are closely related acetyltransferases and transcriptional coactivators. Here, we evaluate the mechanisms by which CBP/p300 regulate Treg differentiation and the consequences of CBP/p300 loss-of-function mutations in follicular lymphoma. Transcriptional and epigenetic profiling identified a cascade of transcription factors essential for Treg differentiation. Mass spectrometry analysis showed that CBP/p300 acetylates prostacyclin synthase, which regulates Treg differentiation by altering proinflammatory cytokine secretion by T and B cells. Reduced Treg presence in tissues harboring CBP/p300 loss-of-function mutations was observed in follicular lymphoma. Our findings provide novel insights into the regulation of Treg differentiation by CBP/p300, with potential clinical implications on alteration of the immune landscape. This study provides insights into the dynamic role of CBP/p300 in the differentiation of Tregs, with potential clinical implications in the alteration of the immune landscape in follicular lymphoma.